|
J Biol Chem, Vol. 273, Issue 43, 27904-27910, October 23, 1998
Metallothionein Induction in Response to Restraint Stress
TRANSCRIPTIONAL CONTROL, ADAPTATION TO STRESS, AND ROLE OF
GLUCOCORTICOID*
Kalpana
Ghoshal ,
Yijie
Wang ,
John F.
Sheridan§¶ , and
Samson T.
Jacob §**
From the Departments of Medical Biochemistry and
Medical Microbiology and Immunology and the
§ Comprehensive Cancer Center, Ohio State University College
of Medicine and the ¶ Section of Oral Biology, Ohio State
University College of Dentistry, Columbus, Ohio 43210
 |
ABSTRACT |
Metallothioneins (MT) have been implicated in the
protection of cells from oxidative stress. We studied the molecular
mechanism of induction of MT-I and MT-II in response to restraint
stress using a mouse model system in which the animals were restrained in well ventilated polypropylene tubes for 12 h each day (one cycle). Here, we show that MT-I and MT-II mRNA levels were elevated as much as 10-20-fold after just one cycle of this simple stress. Stress-mediated MT induction occurred at the transcriptional level. The
level of MT mRNA correlated with the stress-induced increase, and
not with the diurnal variation, in the level of serum glucocorticoid. Treatment of the mice with RU 486, a glucocorticoid receptor
antagonist, prior to restraint stress inhibited MT induction by at
least 50%. Furthermore, the glucocorticoid responsive element-binding
activity in the liver nuclear extracts from the stressed mice was
significantly higher than that in the control mice. The complex
formations between the transcription factor Sp1, MTF1, or MLTF/ARE and
the respective specific oligonucleotides were not altered in the liver
from the stressed mouse. The MT mRNA levels returned to the basal
level at the end of nine cycles of stress, indicating habituation of the animals to restraint stress. At this stage, exposure of the animals
to another type of stress, treatment with heavy metals, resulted in
further induction of MT. These data indicate that glucocorticoid is the
primary physiological factor responsible for MT induction following
restraint stress, and the glucocorticoid receptor is the major
transcription factor involved in this process.
 |
INTRODUCTION |
Metallothionein (MT)1
genes that encode low molecular mass, cysteine-rich, heavy
metal-binding proteins have been reported in a wide variety of
organisms (for reviews, see Refs. 1-4). The members of the MT
superfamily are usually devoid of aromatic amino acids, and each mole
of the protein can bind up to 7-12 g atoms of transition metal through
the abundant cysteine residues. Of the four isoforms of MT, MT-I and
MT-II have been studied the most. Although detoxification of heavy
metals has been considered an important function of MT, recent studies
have suggested a significant role for MT-I and MT-II in copper
homeostasis (1, 3, 5), as a donor of zinc for the
zinc-dependent transcription factors (4), and as a free
radical scavenger in the protection of cells against reactive oxygen
intermediates (6, 7) and electrophilic anticancer drugs (8). These MT
isoforms are transcriptionally induced in response to different stimuli
that include steroid hormones, interleukins, phorbol esters, and
interferons (1, 3). Several lines of evidence suggest that
metallothioneins can protect cells from damage caused by a variety of
agents. For example, overexpression of MT in cells diminishes the
sensitivity of the cells to the compounds that generate free oxygen
radicals (6, 7), DNA-damaging agents such as UV radiation, nitric oxide
(2, 9, 10), and certain anticancer drugs (8, 11), whereas targeted
disruption of the genes renders the cells significantly more sensitive
to cadmium, the oxidant tert-butyl hydroperoxide, and the
herbicide paraquat (12, 13). A recent study has shown that
overproduction of MT selectively in the heart can protect transgenic
mice from the cardiotoxic effects of the potent anticancer drug
Adriamycin (14). Similarly, cells that are resistant to the anticancer
drug cisplatin exhibit high levels of MT (11, 15). In general, the
cells that are resistant to heavy metals and to free oxygen or hydroxyl
radicals tolerate these insults by producing relatively high levels of
MT. These studies have provided considerable impetus to study the
molecular mechanisms of MT induction.
In addition to heavy metals and other agents, stress can also induce MT
(16-19). The unique characteristic of this observation is that
metallothionein can be induced in the absence of any external compounds. The induction of MT in response to restraint stress probably
protects the tissues from the free radicals generated by stress-induced
pro-inflammatory cytokines (20). Only a limited study has been done on
the elucidation of the physiological factors involved in
stress-mediated MT gene activation (16, 21). Although the levels of
glucocorticoids and catecholamines are elevated in response to
restraint stress (22, 23), their roles in the transcriptional control
of stress-mediated MT induction have not been studied in depth. None of
the scanty reports on MT induction under this condition have examined
the MT mRNA levels in the tissues at different time intervals
following stress. An important issue is whether the level of MT
mRNA is restored to the control level after prolonged stress as a
result of habituation of the animals to restraint stress. Furthermore,
although almost all types of MT induction appear to be mediated by MT
promoter activation, it has not been proven experimentally whether the
level of MT mRNA augmented by stress occurs at the transcriptional
or post-transcriptional level or both. The nature of the transcription
factor(s) responsible for MT induction in response to stress has also
not been explored.
Several factors are known to modulate transcription of MT genes. The
most widely studied of these factors is MTF1, a 70-80-kDa polypeptide
with six zinc fingers that is required for both basal and heavy metal-
and oxygen-free radical-induced expression of MT (24-27). In addition
to this protein, other well defined transcription factors such as Sp1
and USF/MLTF can bind to their cognate elements on the MT-I and MT-II
genes (24, 28, 29). Their activation in response to different agents
could have profound effects on the MT promoter activity. Two additional
factors characterized in our laboratory, C'BP-1 (30) and C'BP-2 (31),
interact with the MRE-c' sequence (located between 135 and 110 with
respect to the initiation site) on the MT-I gene and transactivate the MT-I promoter. Any one of the above factors could be involved in MT
induction in response to physical stress. Since the cadmium-induced increase in MT mRNA levels does not appear to be mediated by direct activation of MTF1 (32), as opposed to its activation by zinc, the
induction of MT by different stimuli may be brought about by the
modification of distinct factors specific for each stimulus.
Studies on MT induction by physical stress usually subject the animals
to complete immobilization for a relatively long period, which can lead
to considerable trauma. We took advantage of a mouse model system
developed in our laboratory (33) in which the mice were restrained in
well ventilated polypropylene tubes for 12 h each day. The animals
were free to move back and forth in the tube. The present study was
undertaken to address the nature of the physiological factor, the
molecular mechanism for the enhanced MT mRNA level, the nature of
the transcription factor, and the potential habituation of the animals
to stress with respect to altered MT expression. This investigation
focused on the liver, where the maximal induction of MT was observed in
the stressed animals.
 |
MATERIALS AND METHODS |
Induction of Stress and Drug Treatment of Mice--
The
4-8-week-old inbred male mice (C57BL/6), maintained on a 12-h
light/dark cycle (lights on at 0600 h), were usually subjected to
restraint stress by keeping them in well ventilated 50-ml conical polypropylene tubes for 12 h each day (from 2100 h until
0900 h). During the restraining period, the mice did not have any
access to food and water. At the end of each restraint cycle, the
animals were allowed access to food and water ad
libitum.
To identify the neuroendocrine factors mediating the restraint-induced
increase in MT expression, the animals were implanted with 21-day
continuous release pellets containing 0.5 mg/pellet RU 486 (a type II
glucocorticoid receptor antagonist) or 0.5 mg/pellet nadolol (a
catecholamine receptor antagonist) along with appropriate vehicle
carrier pellets (all purchased from Innovative Research of America,
Inc., Miami, FL). The optimal drug dosages were determined previously
(34). The pellets released 1.2 mg of drug/kg/day. The doses above this
level yielded the same result. The drugs were implanted subcutaneously
using a 14-gauge trocar 3 days prior to restraint.
Isolation of Total RNA and Northern Blot Analysis--
The
livers from the control and restrained animals were frozen in liquid
nitrogen immediately after removal, and total RNA was isolated by the
guanidinium thiocyanate-acid phenol method and subjected to Northern
blot analysis either using a random-primed, [ -32P]dCTP-labeled mouse MT-I minigene (pMT-I i)
(35) or [ -32P]dATP-tailed deoxyoligonucleotides
specific for mouse MT-I and MT-II (36). The blots were subjected to
PhosphorImager analysis, and the 32P signal in each lane
was quantitated by the Volume Analysis program (Molecular Dynamics,
Inc.). The blots were also subjected to autoradiography. To verify that
equal amounts of RNA were loaded onto each lane, the blots were
stripped off the MT-I probe following the manufacturer's protocol and
then re-probed with random-primed, [ -32P]dCTP-labeled
rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA (37). To
distinguish between MT-I and MT-I mRNAs, we used antisense
oligonucleotides specific for mouse MT-I and MT-II (36). These
oligonucleotides are labeled at the 3'-end with
[ -32P]dATP catalyzed by terminal
deoxynucleotidyltransferase.
Nuclear Run-on Transcription--
The nuclei were isolated from
the livers of the mice as described by Gorski et al. (38),
and 5 × 107 nuclei were incubated with ATP, GTP, CTP,
and [ -32P]UTP at 30 °C for 10 min. The labeled RNA
was isolated and used for hybridization overnight (5 × 106 cpm/ml) in Rapid Hybridization Buffer (Amersham
Pharmacia Biotech) to different plasmids immobilized on nylon membrane.
To determine the specific changes in the level of the MT-I transcript,
the plasmid DNA that contains GAPDH (a housekeeping gene), pBS/SK (the
control vector), and MT-I genomic DNA were used. The signals in the
slots containing the immobilized plasmids were measured by
PhosphorImager analysis and quantitated as described above. Graphical
representation of PhosphorImager data was performed using Kaleidagraph
3.0 (Synergy software).
Preparation of Nuclear Extracts--
Nuclei were isolated from
the liver as described by Gorski et al. (38), and nuclear
extracts from the control and restrained mice were prepared according
to the protocol of Wadzinski et al. (39). These extracts
were adequate for the detection of the DNA-binding proteins by
electrophoretic mobility shift assay (EMSA). The protein in the
extracts was estimated using Bio-Rad protein assay reagent with bovine
serum albumin as a standard.
Measurement of Serum Glucocorticoid--
The serum
corticosterone level was measured by radioimmunoassay using a
125I-labeled corticosterone kit (ICN Biochemical, Inc.,
Costa Mesa, CA) at different time points after releasing the animals
from one cycle of stress. Serum samples from four to five mice were pooled for each glucocorticoid measurement. We have demonstrated that
the experimental error in measuring corticosterone using a commercial
kit is <10% (23).
Assay of the DNA-binding Activities of the Transcription
Factors--
The DNA-binding activities of some of the well
characterized transcriptional activators for MT-I were measured by
EMSA. The nuclear extracts were prepared from the livers of the control and stressed mice and incubated with
[ -32P]dGTP-labeled specific oligonucleotides under
optimal conditions. The DNA-protein complexes were separated by
polyacrylamide gel electrophoresis under nondenaturing conditions,
subjected to autoradiography, and quantitated by PhosphorImager
analysis. The deoxyoligonucleotides used for EMSA correspond to MRE-d
(40), MRE-s (40), Sp1 (Promega), MLTF/ARE (40), MLTF (Santa Cruz
Biotechnology), and AP-1 (Promega). For GRE-binding activity, we used
one of the two GRE consensus sequences located upstream of the mouse
MT-I and MT-II genes (41), whose sequence is as follows (Sequence
1).
The underlined sequence corresponds to the GRE consensus for the
mouse MT-I/MT-II gene. The mutant GRE was obtained from Santa Cruz
Biotechnology.
 |
RESULTS |
Restraint Stress Induces MT Expression in the Livers of C57BL/6
Mice--
We used Northern blot analysis to measure MT-I and MT-II
mRNA levels in the livers of C57BL/6 mice restrained for different days and compared them with those of home-cage control mice (Fig. 1). Restraining for one cycle (12 h)
dramatically increased MT-I and MT-II mRNA levels (Fig.
1A, compare lanes 1 and 2).
PhosphorImager analysis of the Northern blots and quantitation of
32P signals (see "Materials and Methods") showed ~10-
and 20-fold increases in the mRNA levels (Fig. 1B) for
MT-I and MT-II, respectively. This enhanced level of MT-I and MT-II
persisted for up to five cycles of restraint (Fig. 1A,
lanes 3 and 4). The mRNA levels of both
isoforms followed a similar pattern, although the level of MT-II was
higher than that of MT-I. MT-I and MT-II mRNA levels started to
fall after seven cycles (Fig. 1A, lane 5), and
after nine cycles, they came down almost to the basal level (lane
6), suggesting habituation or adaptation of the animals to
restraint stress with respect to induction of MT. We also measured the
MT-III mRNA level in the livers of normal and restrained mice, but
did not find any significant increase (data not shown). This is not surprising, as the expression of MT-III is largely confined to the
brain (42).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 1.
A, levels of MT-I and II mRNAs in
the livers of mice restrained for different days. Total RNAs were
isolated from the livers of normal mice and mice restrained for
different days (see "Materials and Methods" for details). RNA (30 µg) was separated by formaldehyde-agarose (1.2%) gel
electrophoresis, transferred to nylon membrane, and subjected to
Northern blot analysis with a 32P-labeled antisense
oligonucleotide specific for mouse MT-I (upper panel). The
blot was washed and subjected to autoradiography and to PhosphorImager
analysis to quantitate the signal. The blot was then stripped off the
probe and rehybridized to a 32P-labeled antisense
oligonucleotide specific for mouse MT-II (middle panel) and
finally to random-primed, 32P-labeled GAPDH cDNA
(lower panel). Lane 1 indicates the mRNA
levels in normal mouse liver (control (C)), and lanes
2-6 represent those in the livers of mice restrained for 1, 3, 5, 7, and 9 days (d), respectively. The lower panel
shows the level of GAPDH mRNA in each lane. B,
graphical representation of MT-I and MT-II mRNA
induction after different cycles of restraint stress (RST).
The 32P signal for MT-I/MT-II mRNA in the control liver
normalized to that of GAPDH was arbitrarily assigned the value of 1. -Fold induction was calculated by comparing the MT-I/MT-II signal in
each time point normalized to the GAPDH signal to that of the control
value. The results are the mean of three independent experiments on
pooled liver RNA from each group consisting of four to five animals.
The open and cross-hatched bars represent the
MT-I and MT-II mRNA levels, respectively.
|
|
The MT mRNA Level Correlates with the Glucocorticoid Level in
the Livers of Mice Restrained for One Cycle--
The basal level of
MT-I mRNA in the livers of the untreated mice was markedly low
(Fig. 2A, lane 1)
and did not change significantly at different times of the day.
Restraint stress can elevate serum glucocorticoid levels (23), and
treatment with glucocorticoid is known to induce MT in cell culture and
animals (43, 44). It was therefore logical to assume that the MT
mRNA level will increase if it is regulated by glucocorticoid
during restraint stress. To address this issue, we restrained mice for
one cycle (1800 to 0600 h) and killed them at different times of
the day following stress, and the liver MT-I mRNA levels were
determined by Northern blot analysis. As anticipated, there was a
significant increase in the liver MT-I mRNA level after
one cycle of stress, as compared with that in untreated mice (Fig.
2A, compare lane 1 with lanes 2-4).
The level of MT-I mRNA was highest at 0600 h, immediately
after release from the restraint, and was 30-fold greater than the
control level (Fig. 2A). The mRNA level then dropped
gradually with time (compare Fig. 2A, lane 2 with
lanes 3 and 4). The higher level of MT mRNA
in this experiment compared with that observed in the time course study
(Fig. 1) is due to the use of the MT-I minigene as a probe in the
Northern blot assay (Fig. 2), which measures both MT-I and II mRNA
levels. We also measured the serum corticosterone level at different
times following one cycle of restraint stress (see "Materials and
Methods"). The serum glucocorticoid level in the restrained mice was
~3.5-fold higher than that in the control animals at the 0600-h time
point. The glucocorticoid level started to decline thereafter and
reached the minimal level at 1200 h, whereas in the untreated
mice, it began to rise at this time. Interestingly, at 1200 h, the
level of corticosterone in the restrained mice declined below that in the control mice. This apparent feedback regulation of the
corticosterone level following restraint stress has been observed
before (23). After 1200 h, the serum glucocorticoid level in the
restrained mice began to rise and reached the same level as that in the
untreated mice at 1800 h, probably due to circadian control of the
glucocorticoid level. Because there was no further increase in the MT-I
mRNA level at 1800 h, either in the restrained or control mice
(Fig. 2A, compare lanes 3 and 4),
these results indicate that MT-I expression is not controlled by
circadian variation of glucocorticoid, but rather by the stress-induced
elevation of the serum glucocorticoid level.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 2.
A, level of MT mRNA in the livers of
restrained mice at different times of the day. Mice were restrained for
12 h (1800 to 0600 h), and total RNA was isolated from the
livers at 0600, 1200, and 1800 h. RNA was isolated from the livers
of control mice killed at the same time. Total RNA (30 µg) was
subjected to Northern blot analysis with the random-primed,
32P-labeled MT-I minigene
(BglII-HindIII fragment of the MT-I minigene),
pMT-I i (upper panel). Since the MT-I mRNA level in
normal mouse liver did not change during the day, only the 0600-h
control (C) sample is shown (lane 1). Lanes
2-4 represent the MT-I mRNA levels in the livers of mice
restrained for one cycle and killed at 0600, 1200, and 1800 h,
respectively. The lower panel shows the level of GAPDH
mRNA in each lane. B, serum corticosterone level at
different times of the day in the control mice and mice restrained for
one cycle. Blood was collected from each mouse (each group consisted of
five animals for each time point) immediately before death, and the
pooled sera from five mice were used to measure the corticosterone
level by radioimmunoassay. The open and cross-hatched
bars denote the corticosterone levels in the sera of the control
and restrained mice, respectively. RST, restraint
stress.
|
|
The Glucocorticoid Receptor Antagonist RU 486 Partially Blocks the
Stress-induced Elevation of the MT mRNA Level, whereas the
Catecholamine Receptor Antagonist Nadolol Has No Effect--
We then
investigated the nature of the physiological inducer for MT-I during
restraint stress. It is known that stress activates the
hypothalamus-pituitary-adrenal gland axis as a result of which plasma
glucocorticoid and catecholamine levels are elevated (22, 23). These
agents can, in turn, modulate expression of different target genes in
various tissues depending on the availability of their receptors on
target tissues. To determine which of these agents activates expression
of MTs in the liver during restraint stress, a sustained release pellet
of the type II glucocorticoid receptor antagonist RU 486 was implanted
subcutaneously in the mice 3 days prior to restraint. As a control, the
mice were implanted with the same pellet without the drug. After three
cycles of restraint, the mice were killed, and total RNA isolated from
the liver was subjected to Northern blot analysis with the MT-I
minigene as a probe (Fig. 3A).
As expected, there was a significant increase in the MT mRNA level
after 3 days of restraint stress (Fig. 3A, compare
lanes 1 and 2). The MT-I mRNA level in the
livers of restrained mice mock-implanted without the drug was almost
identical to that in the control (no implantation) restrained mice
(Fig. 3A, lane 3), whereas the MT-I mRNA
level decreased by at least 50% in the liver of restrained mice
implanted with RU 486 (Fig. 3, A, lane 4; and
B). This result clearly shows that the induction of MT-I or
MT-II in response to stress is at least partially mediated by
glucocorticoids.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
A, level of MT mRNA in the livers of
restrained mice implanted with the glucocorticoid receptor antagonist
RU 486. Mice were implanted with RU 486 or a placebo 3 days before
restraint. After three cycles of restraint, the liver RNA was isolated
from these mice as well as normal and non-implanted restrained mice.
Total RNA (30 µg) was subjected to Northern blot analysis with the
MT-I minigene (upper panel) or GAPDH cDNA (lower
panel) as a probe. Lanes 1-4 represent the mRNA
levels in the livers of normal mice (Control), restrained
mice (RST), restrained mice implanted with a placebo pellet
(RST+PL), and restrained mice implanted with an RU 486 pellet (RST+RU), respectively. Since the MT-I minigene used
in the Northern blot assay hybridizes to both MT-I and MT-II mRNAs
as they are highly homologous, mRNA signals correspond to both
isoforms (unlike the data represented in Fig. 1). B,
graphical representation of the effect of RU 486 on the
restraint stress-induced elevation of MT mRNA levels. The
32P signal for MT-I/MT-II mRNA in the control liver
normalized to that of GAPDH was arbitrarily assigned the value of 1. -Fold induction was calculated by comparing the MT signal in each
treatment group normalized to the GAPDH signal to that of the control
value. Lanes 1-3 represent -fold induction of MT in the
livers of restrained (RST), restrained placebo-implanted
(RST+PL), and restrained RU 486-implanted
(RST+RU) mice, respectively. The results are the mean of
three independent experiments on pooled liver RNA from each group
consisting of four to five animals. C, level of
MT mRNA in the livers of restrained mice implanted with the
catecholamine receptor antagonist nadolol. Mice were implanted with a
sustained release pellet of nadolol or with a placebo 3 days prior to
restraint, and after three cycles of stress, total RNA from the livers
was subjected to Northern blot analysis with the MT-I minigene
(upper panel) or GAPDH cDNA (lower panel) as
a probe. Lanes 1-3 represent the mRNA levels in the
nadolol-implanted control mice, restrained placebo-implanted mice
(RST+PL), and restrained nadolol-implanted mice
(RST+NAD), respectively.
|
|
Since MT induction in the liver in response to restraint stress was not
completely blocked by the glucocorticoid receptor antagonist, it is
likely that other factors released from the hypothalamus-pituitary-adrenal gland axis, namely catecholamines, might
play a role in MT induction. It is known that administration of
epinephrine and norepinephrine to animals can activate MT genes (1). To
study the potential role of catecholamines in the induction of MT in
response to stress, a sustained release pellet of nadolol, a
-adrenergic receptor antagonist, was implanted in the mice (34). The
drug implanted in normal mice had no effect on the MT-I mRNA level
(Fig. 3C, lane 1). The livers of mice implanted with a placebo (Fig. 3C, lane 2) or implanted
with nadolol (lane 3) exhibited a similar level of MT
mRNA (compare lane 1 with lanes 2 and 3). This study demonstrates that MT-I induction in the
liver in response to stress is not mediated by the physiological
effectors catecholamines and that glucocorticoid is a major
physiological mediator of the stress-induced alteration of MT
expression.
MT Induction in the Liver in Response to Restraint Stress Occurs at
the Level of Transcription--
Northern blot analysis, which
determines the steady-state level of an mRNA, can be due to either
transcriptional or post-transcriptional control mechanisms. The altered
expression of MT-I and MT-II by different agents occurs primarily at
the level of transcription (28, 45, 46). To establish that this
mechanism is responsible for the augmented level of MT-I mRNA
following restraint stress, a nuclear run-on transcription assay was
performed. In this experiment, nuclei isolated from the livers of
normal mice and mice restrained for one cycle were labeled with
[ -32P]UTP, and the 32P-labeled RNA
(identical counts/min) was hybridized to different plasmid DNAs
immobilized on a nylon membrane (Fig. 4).
The MT transcript level in the liver nuclei from the stressed mice was significantly (20-fold) higher than that in the control liver nuclei,
whereas the GAPDH transcript level was identical in both control and
restrained samples. This experiment demonstrates that the restraint
stress-mediated induction of MT occurs largely at the level of
transcription. Since the extent of stimulation (20-fold) of MT-I
transcription is consistent with the stimulation observed by Northern
blot analysis of RNA, the MT-I induction following restraint stress
must occur largely at the transcriptional level.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 4.
Transcription in isolated nuclei (run-on
transcription) from the livers of control and restrained mice.
Nuclei isolated from the control mice and the mice restrained
(RST) for one cycle were incubated with
[ -32P]UTP, and total RNA containing the same
counts/min was used as a probe to hybridize to different plasmid DNAs
(see "Materials and Methods" for details). Lanes 1 and
2 represent 5 and 10 µg of pBS/SK vector plasmid,
respectively; lanes 3 and 4 correspond to 5 and
10 µg of the plasmid containing mouse MT-I genomic DNA, respectively;
and lanes 5 and 6 represent 5 and 10 µg of rat
GAPDH cDNA, respectively.
|
|
The Glucocorticoid Receptor (GR) Is Significantly Activated in the
Livers of Mice Subjected to Restraint Stress--
As MT induction in
response to restraint stress occurs primarily at the level of
transcription, we next explored the transcription factors that are
probably activated under this condition to facilitate MT expression.
For this purpose, we measured the DNA-binding activities of the factors
Sp1, MTF1, MLTF, and GR, which bind to and transactivate the MT-I
promoter. Although the inducibility of mouse MT by direct administration of glucocorticoids in vivo has been known
(43, 44), the glucocorticoid response element (GRE), which confers glucocorticoid response, was identified in the upstream region of the
MT gene only recently (41). This element is located 7 kilobases
upstream of the MT-I gene and 3 kilobases upstream of the MT-II gene
and consists of two GRE consensus sequences separated by a few base
pairs. The two GRE sequences present in the mouse MT promoter differ
from the GRE consensus element (GGTACAnnnTGTTCT) in two or three
positions, but can still bind to the recombinant GR and can also
mediate dexamethasone-mediated activation of the MT genes in
transfected cells (41). We synthesized a deoxyoligonucleotide spanning
one of these GREs and used it as a probe in EMSA using nuclear extract
from the liver. A specific DNA-protein complex was detected in the
normal mouse liver nuclear extract (Fig.
5A, lane 1), which
could be competed with a 100-fold molar excess of the wild-type GRE
(lane 3), but not with the mutant GRE (lane 4).
Compared with the control extract, there was 4-fold increase in the
GRE-binding activity in the liver nuclear extract prepared from mice
restrained for three cycles (Fig. 5A, compare lanes 1 and 2), which could be competed with the wild-type
GRE (lane 5), but not with the mutant GRE (lane
6). We also measured the DNA-binding activities of three other
factors by EMSA with specific oligonucleotides in the same nuclear
extract. MTF1 is a factor required for basal as well as induced
transcription of MT in response to heavy metals (24) and oxidative
stress (40, 47). Its DNA-binding activity was measured in the liver
nuclear extract with the MRE-d oligonucleotide. Since MRE-d contains
the binding sites for both Sp1 and MTF1, two complexes corresponding to
these factors were formed (Fig. 5B, compare lanes
1 and 2). Competitive EMSA with the unlabeled Sp1
oligonucleotide formed a complex containing only MTF1 (Fig.
5B, lanes 3 and 4), whereas
competition with the MRE-s oligonucleotide (a variant form of MRE-d in
which the Sp1 site is mutated and that selectively interacts with MTF1)
produced the Sp1-specific complex (lanes 5 and
6). There was no significant change in the DNA-binding
activities of the factors Sp1 and MTF1 in the nuclear extract from the
restrained mouse liver (Fig. 5B, compare lanes
4 and 6 with lanes 3 and
5, respectively). MLTF is another factor that is involved in
the constitutive expression of MT genes (29). It binds to the composite
MLTF/ARE sequence of the MT-I promoter. In the liver nuclear extracts
from the control and restrained mice, a prominent complex was detected
with the MLTF/ARE oligonucleotide (Fig. 5C, lanes
1 and 2, respectively), which could be competed with
the MLTF oligonucleotide (lane 3) or the MLTF/ARE
oligonucleotide (lane 4), but not with the AP-1 consensus
oligonucleotide (lane 5) or the MRE-s oligonucleotide (lane 6). These results show that MLTF is the only factor in
the liver nuclear extract that binds to the MLTF/ARE sequence, and it
was not significantly altered after restraining the mice (Fig. 5C, compare lanes 1 and 2). The higher
activity in lane 6 is probably due to slight overloading of
the sample, as the level of the MLTF complex in all other lanes was
nearly identical. We conclude that among the factors that bind to and
transactivate the MT-I promoter, only GR activity is significantly
elevated in response to restraint stress.

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 5.
EMSA using liver nuclear extracts from normal
and restrained mice and 32P-labeled MRE-d and MLTF/ARE
oligonucleotides as probes. Identical amounts (10 µg) of liver
nuclear extracts from the control and restrained mice were incubated
with the 32P-labeled oligonucleotides under optimal binding
conditions (see "Materials and Methods" for details), and the
DNA-protein complexes were separated by polyacrylamide (4% acrylamide)
gel electrophoresis with 0.25× Tris borate/EDTA (for MRE-d) or 1× TG
(for the GRE and MLTF/ARE) as running buffer. The gel was transferred
to blotting paper, dried, and subjected to autoradiography and
PhosphorImager analysis for quantitation. A,
GRE-binding activities in liver nuclear extracts from the
control (C) and restrained (R) mice. Lanes
1 and 2 indicate the complexes formed with 10 µg of
the extracts from the control and restrained mice, respectively.
Lanes 3 and 4 represent the complexes formed with
the extract from the control mice after preincubation with a 100-fold
excess of unlabeled wild-type (WT) and mutant
(MUT) GREs, respectively. Lanes 5 and
6 denote the complexes formed with the nuclear extracts from
the restrained mice after preincubation with an excess of wild-type and
mutant GREs, respectively. GR indicates the specific
glucocorticoid receptor complex. B, DNA-binding
activities of MTF1 and Sp1 in the liver nuclear extracts from the
control and restrained mice. Lanes 1 and 2 indicate the complexes formed with 10 µg of the extracts from the
control and restrained mice, respectively. Lanes 3 and
4 represent the complexes formed with the extracts from the
control and restrained mice after preincubation with a 100-fold excess
of the unlabeled Sp1 consensus oligonucleotide, respectively.
Lanes 5 and 6 denote the complexes
formed with the extracts from the control and restrained mice after
preincubation with a 100-fold excess of the MRE-s oligonucleotide,
respectively. C, DNA-binding activities of
USF/MLTF in the liver nuclear extracts from the control and restrained
mice. Lanes 1 and 2 represent
MLTF-oligonucleotide complexes formed with 10 µg of the extracts from
control and restrained mice, respectively. Lanes 3-6
represent the complexes formed in restrained mouse extract after
preincubation with a 100-fold molar excess of MLTF, MLTF/ARE, AP-1, and
MRE-s oligonucleotides, respectively.
|
|
MT Is Induced in the Livers of Mice Habituated to Restraint Stress
in Response to a Different Stress Condition--
This study has shown
that the mRNA levels of MT-I and MT-II returned to the basal level
when restraint stress was prolonged for several cycles. This
restoration of MT induction to the basal level suggests that these
animals habituate to this stressor. The stimulus from the
hypothalamus-pituitary-adrenal gland axis may subside after prolonged
stress, as a result of which MT-I and MT-II genes are turned off. To
test this possibility, we injected the mice restrained for 9 days and
home-cage control mice with ZnSO4 and CdSO4.
The control group was injected with the same volume of physiological
saline. Normal mice injected with saline showed a very low level of
MT-I mRNA (Fig. 6, lane
1), which increased significantly after treatment with zinc
sulfate (lane 2) or cadmium sulfate (lane 3).
Similarly, restrained mice injected with saline showed MT-I mRNA
levels 2-3-fold higher than the control group (Fig. 6, compare
lanes 1 and 4), and this level increased
significantly after zinc (lane 5) or cadmium (lane
6) treatment. These results showed that after 9 days of restraint,
the mice could still respond to a second stimulus or stressor.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 6.
Level of MT-I mRNA in the livers of mice
restrained for 9 days and then challenged with CdSO4 or
ZnSO4. Normal (Control) mice and restrained
(RST) mice (9 days) were injected with physiological saline
or with CdSO4 (15 µmol/kg of body weight) or
ZnSO4 (50 µmol/kg of body weight) dissolved in saline.
After 4 h, total RNA was isolated from the livers of these mice,
and 30 µg of RNA was subjected to Northern blot analysis with MT-I
cDNA (upper panel) or GAPDH cDNA (lower
panel). Lanes 1-3 represent MT-I mRNA levels in
the livers of normal mice injected with saline, ZnSO4, and
CdSO4, respectively. Lanes 4-6 indicate
mRNA levels in the livers of restrained mice injected with saline,
ZnSO4, and CdSO4, respectively.
|
|
 |
DISCUSSION |
Previous studies on the stress-induced changes in MT expression
used animals that were completely immobilized by fixing them to a board
or enclosing them in a wrapping of metallic net (18, 19), whereas this
investigation utilized a mouse model system that has been explored
extensively for determining the neuroendocrinological changes under
stress (20, 22, 23, 34, 48, 49). The merit of this model system is that
the animals are free to move around, and the only restriction is the
inability to turn around in the conical tube. Furthermore, the animals
had free access to food and water after each cycle of restraint that
lasted 12 h, which permitted us to explore the physiological
adaptation after a few cycles of a particular type of stressor. Another
advantage of this model system is that one can investigate in an animal system whether distinct molecular mechanism(s) exists for MT induction in response to a variety of physical and chemical stresses that are
known to increase the level of MT.
Although the MT-I and MT-II levels are known to increase following
complete immobilization stress (17, 18, 21), the molecular mechanisms
of this induction have not been elucidated. We have demonstrated for
the first time that MT induction by restraint stress occurs at the
transcriptional level. It is unlikely that MT induction is also
mediated by post-transcriptional control mechanisms, as the extent of
stimulation observed by Northern blot analysis is similar to that
observed in the nuclear run-on assay. To date, the potential adaptation
or habituation of the animals with respect to MT induction in response
to different types of stress has not been investigated. This study has
shown that the mRNA levels of mouse metallothioneins I and II are
dramatically elevated in the liver in response to a relatively simple
physical stress condition and that the augmented level of MT mRNA
returned to the constitutive level after several cycles of repeated
stress. The precise mechanism(s) for this down-regulation is unclear. Interestingly, the mRNA levels increased again in response to a
different stressor, exposure to heavy metals. The MT protein level also
correlated well with alterations of the mRNA levels (data not
shown). Under this condition, the mRNA levels of two other
stress-inducible proteins, namely heme oxygenase I and hsp70, were not
elevated (data not shown), although these genes, like MT, can be
induced by cadmium (50, 51). To our knowledge, this is the first report
of the habituation of animals to restraint stress with respect to MT
expression.
There have been conflicting reports concerning the role of
glucocorticoid in the stress-mediated increase in MT levels. Hidalgo et al. (21) reported that RU 486 treatment activates basal
or stress-mediated increases in MT levels. Subsequently, the same investigators claimed that restraint stress-induced glucocorticoid augments MT mRNA synthesis (17). We have consistently observed that
inhibition of GR activity suppresses stress-induced increases in the MT
mRNA level by at least 50%. More important, the rise in the MT-I
mRNA level is consistent with the stress-induced increase in the
corticosterone level, rather than the diurnal fluctuations of the
steroid hormone, suggesting regulation by the type II glucocorticoid receptor. To our knowledge, this is the first report showing that MT
genes can be induced by physiological alteration of the level of
corticosterone, the natural glucocorticoid for rodents. The role of
glucocorticoid in the stress-mediated induction of MT was established
by the rise in the blood corticosterone concentration after restraint,
as well as by the partial block of MT induction as a result of prior
treatment of the mice with the glucocorticoid receptor antagonist RU
486. Furthermore, the absence of MT induction after nine cycles of
stress is consistent with the decrease in the serum glucocorticoid
level after prolonged exposure to stress (23). Since the augmented MT
expression is not inhibited by nadolol, a -adrenergic receptor
antagonist, the catecholamines are not likely to be involved in this
process. Alternatively, the stress-mediated release of opioids may also
contribute to the activation of the MT promoter under this condition.
Further study is required to test the latter possibility.
This study also explored the nature of the transcription factor(s) that
may be activated by restraint stress. Since glucocorticoids play a key
role in MT induction by stress, it was logical to conceive that the
glucocorticoid receptor may be activated following stress. Although it
has been known for a long time that dexamethasone treatment of animals
as well as cells in culture induces MT genes, the cis-acting
sequence (GRE) regulating the expression was identified in the mouse
promoter only recently (41). Either one of the two copies of the GRE
located upstream of MT-II can bind to the recombinant GR and is solely
responsible for dexamethasone-mediated activation of both MT genes.
Using one of these GRE oligonucleotides, we have shown that the
DNA-binding activity of the GR is enhanced 3-5-fold in liver extracts
from the stressed animals. The DNA-binding activity of the GR was
observed only with the oligonucleotide corresponding to the wild-type
GRE, but not with the oligonucleotide corresponding to the mutant GRE
and liver nuclear extracts, which further confirms the role of the GR
in MT induction by restraint stress.
We also investigated whether the activities of other key transcription
factors, e.g. Sp1 and USF/MLTF, are altered by stress. The
DNA-binding activities were unaltered under this condition. MTF1 is
another factor that has been established to have an important role in
the basal and induced expression of MT. It was logical to study the
effect of restraint stress on the activity of this factor.
Surprisingly, this factor was not activated by this inducer. These data
suggest that the mechanism of induction of MT by stress is distinct
from that by chemical stress (e.g. heavy metals) that is
mediated by MTF1. The glucocorticoid receptor appears to be the major
factor positively regulated by restraint stress and is known to bind a
specific glucocorticoid response element located upstream of the MT-I
or MT-II gene. Recently, a mutant mouse strain was generated in which
the DNA-binding activity of the GR was abolished without affecting the
ligand binding and transactivating functions (52). These mice will a
useful tool to study further the role of stress-induced release of
glucocorticoid in induction of MTs and other immunomodulatory
factors.
 |
ACKNOWLEDGEMENTS |
We are grateful to Dr. Richard Palmiter for
providing the mouse MT-I clone and Dr. Pal Vaghy for advising us on the
Kaleidagraph Program.
 |
FOOTNOTES |
*
This work was supported in part by Grant CA 61321 from NCI
(to S. T. J.) and by Grant R01-MH 46801 from the National Institute of Mental Health and Grant P01-AG 11585 from NIA (to J. F. S.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence should be addressed: Ohio State University,
333 Hamilton Hall, 1645 Neil Ave., Columbus, OH 43210. Tel.:
614-688-5494; Fax: 614-688-5600.
The abbreviations used are:
MT, metallothionein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; EMSA, electrophoretic
mobility shift assay; GR, glucocorticoid receptor; GRE, glucocorticoid
response element.
 |
REFERENCES |
-
Kagi, J. A.
(1991)
Methods Enzymol.
205,
613-626[Medline]
[Order article via Infotrieve]
-
Karin, M.
(1985)
Cell
41,
9-10[CrossRef][Medline]
[Order article via Infotrieve]
-
Moffatt, P.,
and Denizeau, F.
(1997)
Drug Metab. Rev.
29,
261-307[Medline]
[Order article via Infotrieve]
-
Vallee, B. L.
(1995)
Neurochem. Int.
27,
23-33[CrossRef][Medline]
[Order article via Infotrieve]
-
Bremner, I.
(1991)
Methods Enzymol.
205,
584-591[Medline]
[Order article via Infotrieve]
-
Pitt, B. R.,
Schwarz, M.,
Woo, E. S.,
Yee, E.,
Wasserloos, K.,
Tran, S.,
Weng, W.,
Mannix, R. J.,
Watkins, S. A.,
Tyurina, Y. Y.,
Tyurin, V. A.,
Kagan, V. E.,
and Lazo, J. S.
(1997)
Am. J. Physiol.
273,
L856-L865[Abstract/Free Full Text]
-
Schwarz, M. A.,
Lazo, J. S.,
Yalowich, J. C.,
Reynolds, I.,
Kagan, V. E.,
Tyurin, V.,
Kim, Y. M.,
Watkins, S. C.,
and Pitt, B. R.
(1994)
J. Biol. Chem.
269,
15238-15243[Abstract/Free Full Text]
-
Kelly, S. L.,
Basu, A.,
Teicher, B. A.,
Hacker, M. P.,
Hamer, D. H.,
and Lazo, J. S.
(1990)
Science
35,
1813-1815
-
Chubatsu, L. S.,
and Meneghini, M., R.
(1993)
Biochem. J.
291,
193-198
-
Schwarz, M. A.,
Lazo, J. S.,
Yalowich, J. C.,
Allen, W. P.,
Whitmore, M.,
Bergonia, H. A.,
Tzeng, E.,
Billiar, T. R.,
Robbins, P. D.,
Lancaster, J. R., Jr.,
and Pitt, B. R.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
4452-4456[Abstract/Free Full Text]
-
Kasahara, K.,
Fujiwara, Y.,
Nishio, K.,
Ohmori, T.,
Sugimoto, Y.,
Komiya, K.,
Matsuda, T.,
and Saijo, N.
(1991)
Cancer Res.
51,
3237-3242[Abstract/Free Full Text]
-
Lazo, J. S.,
Kondo, Y.,
Dellapiazza, D.,
Michalska, A. E.,
Choo, K. H.,
and Pitt, B. R.
(1995)
J. Biol. Chem.
270,
5506-5510[Abstract/Free Full Text]
-
Masters, B. A.,
Kelly, E. J.,
Quaife, C. J.,
Brinster, R. L.,
and Palmiter, R. D.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
584-588[Abstract/Free Full Text]
-
Kang, Y. J.,
Chen, Y., Yu, A.,
Voss-McCowan, M.,
and Epstein, P. N.
(1997)
J. Clin. Invest.
100,
1501-1506[Medline]
[Order article via Infotrieve]
-
Schilder, R. J.,
Hall, L.,
Monks, A.,
Handel, L. M.,
Fornace, A. J., Jr.,
Ozols, R. F.,
Fozo, A. T.,
and Hamilton, T. C.
(1990)
Int. J. Cancer
45,
416-422[Medline]
[Order article via Infotrieve]
-
Hidalgo, J.,
Rhee, S. J.,
Huang, P. C.,
and Garvey, J. S.
(1992)
Horm. Metab. Res.
24,
233-236[Medline]
[Order article via Infotrieve]
-
Hidalgo, J.,
Borras, M.,
Garvey, J. S.,
and Armario, A.
(1990)
J. Neurochem.
55,
651-654[CrossRef][Medline]
[Order article via Infotrieve]
-
Hidalgo, J.,
Armario, A.,
Flos, R.,
and Garvey, J. S.
(1986)
Experientia (Basel)
42,
1006-1010
-
Belloso, E.,
Hernandez, J.,
Giralt, M.,
Kille, P.,
and Hidalgo, J.
(1996)
Neuroendocrinology
64,
430-439[Medline]
[Order article via Infotrieve]
-
Dobbs, C. M.,
Feng, N.,
Beck, F. M.,
and Sheridan, J. F.
(1996)
J. Immunol.
157,
1870-1877[Abstract]
-
Hidalgo, J.,
Giralt, M.,
Garvey, J. S.,
and Armario, A.
(1988)
Am. J. Physiol.
254,
E71-E78[Abstract/Free Full Text]
-
Hermann, G.,
Beck, F. M.,
Tovar, C. A.,
Malarkey, W. B.,
Allen, C.,
and Sheridan, J. F.
(1994)
J. Neuroimmunol.
53,
173-180[CrossRef][Medline]
[Order article via Infotrieve]
-
Hermann, G.,
Tovar, C. A.,
Beck, F. M.,
and Sheridan, J. F.
(1994)
J. Neuroimmunol.
49,
25-33[CrossRef][Medline]
[Order article via Infotrieve]
-
Heuchel, R.,
Radtke, F.,
Georgiev, O.,
Stark, G.,
Aguet, M.,
and Schaffner, W.
(1994)
EMBO J.
13,
2870-2875[Medline]
[Order article via Infotrieve]
-
Radtke, F.,
Heuchel, R.,
Georgiev, O.,
Hergersberg, M.,
Gariglio, M.,
Dembic, Z.,
and Schaffner, W.
(1993)
EMBO J.
12,
1355-1362[Medline]
[Order article via Infotrieve]
-
Radtke, F.,
Georgiev, O.,
Muller, H. P.,
Brugnera, E.,
and Schaffner, W.
(1995)
Nucleic Acids Res.
23,
2277-2286[Abstract/Free Full Text]
-
Brugnera, E.,
Georgiev, O.,
Radtke, F.,
Heuchel, R.,
Baker, E.,
Sutherland, G. R.,
and Schaffner, W.
(1994)
Nucleic Acids Res.
22,
3167-3173[Abstract/Free Full Text]
-
Thiele, D. J.
(1992)
Nucleic Acids Res.
20,
1183-1191[Free Full Text]
-
Carthew, R. W.,
Chodosh, L. A.,
and Sharp, P. A.
(1987)
Genes Dev.
1,
973-980[Abstract/Free Full Text]
-
Aniskovitch, L. P.,
and Jacob, S. T.
(1997)
Arch. Biochem. Biophys.
341,
337-346[CrossRef][Medline]
[Order article via Infotrieve]
-
Aniskovitch, L. P.,
and Jacob, S. T.
(1998)
Oncogene
16,
1475-1486[CrossRef][Medline]
[Order article via Infotrieve]
-
Bittel, D.,
Dalton, T. P.,
Samson, S. L.-A.,
Gedamu, L.,
and Andrews, G. K.
(1998)
J. Biol. Chem.
273,
7127-7133[Abstract/Free Full Text]
-
Sheridan, J. F.,
Feng, N.,
Bonneau, R. H.,
Allen, C. M.,
Huneycutt, B. S.,
and Glaser, R.
(1991)
J. Neuroimmunol.
31,
245-255[CrossRef][Medline]
[Order article via Infotrieve]
-
Dobbs, C. M.,
Vasquez, M.,
Glaser, R.,
and Sheridan, J. F.
(1993)
J. Neuroimmunol.
48,
151-160[CrossRef][Medline]
[Order article via Infotrieve]
-
Glanville, N.,
Durnam, J. D.,
and Palmiter, R. D.
(1981)
Nature
292,
267-269[CrossRef][Medline]
[Order article via Infotrieve]
-
Choudhuri, S.,
Kramer, K. K.,
Berman, N. E.,
Dalton, T. P.,
Andrews, G. K.,
and Klassen, K. D.
(1994)
Toxicol. Appl. Pharmacol.
131,
144-154
-
Fort, P.,
Piechaczyk, M.,
El Sabrouty, S.,
Dani, C.,
Jeanteur, P.,
and Blanchard, J. M.
(1985)
Nucleic Acids Res.
13,
1431-1442[Abstract/Free Full Text]
-
Gorski, K.,
Carneiro, M.,
and Schibler, U.
(1986)
Cell
47,
767-776[CrossRef][Medline]
[Order article via Infotrieve]
-
Wadzinski, B. E.,
Wheat, W. H.,
Jaspres, S.,
Peruski, L. F., Jr.,
Lickteig, R. L.,
Johnson, G. L.,
and Klemm, D.
(1993)
Mol. Cell. Biol.
13,
2822-2834[Abstract/Free Full Text]
-
Dalton, T. P.,
Li, Q.,
Bittel, D.,
Liang, L.,
and Andrews, G. K.
(1996)
J. Biol. Chem.
271,
26233-26241[Abstract/Free Full Text]
-
Kelly, E. J.,
Sandgren, E. P.,
Brinster, R. L.,
and Palmiter, R. D.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
10045-10050[Abstract/Free Full Text]
-
Palmiter, R. D.,
Findley, S. D.,
Whitmore, T. E.,
and Durnam, D. M.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
6333-6337[Abstract/Free Full Text]
-
Hager, L. J.,
and Palmiter, R. D.
(1981)
Nature
291,
340-342[CrossRef][Medline]
[Order article via Infotrieve]
-
Mayo, K. E.,
and Palmiter, R. D.
(1981)
J. Biol. Chem.
256,
2621-2624[Abstract/Free Full Text]
-
Hamer, D. H.
(1986)
Annu. Rev. Biochem.
55,
913-951[Medline]
[Order article via Infotrieve]
-
Palmiter, R. D.
(1987)
Experientia (Basel)
52,
63-80
-
Gunes, C.,
Heuchel, R.,
Georgiev, O.,
Lichtlen, P.,
Bluthmann, H.,
Marino, S.,
Aguzzi, A.,
and Scaffner, W.
(1998)
EMBO J.
17,
2846-2854[CrossRef][Medline]
[Order article via Infotrieve]
-
Hermann, G.,
Tovar, C. A.,
Beck, F. M.,
Allen, C.,
and Sheridan, J. F.
(1993)
J. Neuroimmunol.
47,
83-94[CrossRef][Medline]
[Order article via Infotrieve]
-
Hermann, G.,
Beck, F. M.,
and Sheridan, J. F.
(1995)
J. Neuroimmunol.
56,
179-186[CrossRef][Medline]
[Order article via Infotrieve]
-
Maines, M. D.
(1988)
FASEB J.
2,
2557-2568[Abstract]
-
Mosser, D. D.,
Theodorakis, N. G.,
and Morimoto, R. I.
(1988)
Mol. Cell. Biol.
8,
4736-4744[Abstract/Free Full Text]
-
Reichardt, H. M.,
Kaestner, K. H.,
Tuckermann, J.,
Kretz, O.,
Wessely, O.,
Bock, R.,
Gass, P.,
Schmid, W.,
Herrlich, P.,
Angel, P.,
and Schutz, G.
(1998)
Cell
93,
531-541[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P. S. D. Weber, S. A. Madsen-Bouterse, G. J. M. Rosa, S. Sipkovsky, X. Ren, P. E. Almeida, R. Kruska, R. G. Halgren, J. L. Barrick, and J. L. Burton
Analysis of the bovine neutrophil transcriptome during glucocorticoid treatment
Physiol Genomics,
December 13, 2006;
28(1):
97 - 112.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Majumder, K. Ghoshal, D. Summers, S. Bai, J. Datta, and S. T. Jacob
Chromium(VI) Down-regulates Heavy Metal-induced Metallothionein Gene Transcription by Modifying Transactivation Potential of the Key Transcription Factor, Metal-responsive Transcription Factor 1
J. Biol. Chem.,
July 3, 2003;
278(28):
26216 - 26226.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. G. Edwards, D. Sarkar, R. Klopp, J. D. Morrow, R. Weindruch, and T. A. Prolla
Age-related impairment of the transcriptional responses to oxidative stress in the mouse heart
Physiol Genomics,
April 16, 2003;
13(2):
119 - 127.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Barazzone-Argiroffo, A. Pagano, C. Juge, I. Metrailler, A. Rochat, C. Vesin, and Y. Donati
Glucocorticoids aggravate hyperoxia-induced lung injury through decreased nuclear factor-kappa B activity
Am J Physiol Lung Cell Mol Physiol,
January 1, 2003;
284(1):
L197 - L204.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ghoshal, J. Datta, S. Majumder, S. Bai, X. Dong, M. Parthun, and S. T. Jacob
Inhibitors of Histone Deacetylase and DNA Methyltransferase Synergistically Activate the Methylated Metallothionein I Promoter by Activating the Transcription Factor MTF-1 and Forming an Open Chromatin Structure
Mol. Cell. Biol.,
December 1, 2002;
22(23):
8302 - 8319.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Majumder, K. Ghoshal, J. Datta, S. Bai, X. Dong, N. Quan, C. Plass, and S. T. Jacob
Role of de Novo DNA Methyltransferases and Methyl CpG-binding Proteins in Gene Silencing in a Rat Hepatoma
J. Biol. Chem.,
May 3, 2002;
277(18):
16048 - 16058.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Tanner, A. Abowath, and A. D. Miller
Isothermal Titration Calorimetry Reveals a Zinc Ion as an Atomic Switch in the Diadenosine Polyphosphates
J. Biol. Chem.,
January 25, 2002;
277(5):
3073 - 3078.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ghoshal, S. Majumder, Q. Zhu, J. Hunzeker, J. Datta, M. Shah, J. F. Sheridan, and S. T. Jacob
Influenza Virus Infection Induces Metallothionein Gene Expression in the Mouse Liver and Lung by Overlapping but Distinct Molecular Mechanisms
Mol. Cell. Biol.,
December 15, 2001;
21(24):
8301 - 8317.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Barazzone-Argiroffo, P. Muzzin, Y. R. Donati, C.-D. Kan, M. L. Aubert, and P.-F. Piguet
Hyperoxia increases leptin production: a mechanism mediated through endogenous elevation of corticosterone
Am J Physiol Lung Cell Mol Physiol,
November 1, 2001;
281(5):
L1150 - L1156.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ghoshal, S. Majumder, Z. Li, X. Dong, and S. T. Jacob
Suppression of Metallothionein Gene Expression in a Rat Hepatoma Because of Promoter-specific DNA Methylation
J. Biol. Chem.,
January 7, 2000;
275(1):
539 - 547.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Yoshida, A. Kristiansen, and M. C. Liberman
Heat Stress and Protection from Permanent Acoustic Injury in Mice
J. Neurosci.,
November 15, 1999;
19(22):
10116 - 10124.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Cai and J. F. Hyde
The Human Growth Hormone-Releasing Hormone Transgenic Mouse as a Model of Modest Obesity: Differential Changes in Leptin Receptor (OBR) Gene Expression in the Anterior Pituitary and Hypothalamus after Fasting and OBR Localization in Somatotrophs
Endocrinology,
August 1, 1999;
140(8):
3609 - 3614.
[Abstract]
[Full Text]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|